Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas
Journal of Investigative Dermatology · 2026-09
DOI: 10.1016/j.jid.2026.08.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2026-09. Verfasst von Ali Azimi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia; Department of Dermatology, Westmead Hospital…. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Western Sydney Local Health District.
Abstract (Originalsprache)
Cutaneous squamous cell carcinoma is a heterogeneous skin malignancy worldwide. Although most tumors are effectively treated by surgical excision, between 5 and 37% of biologically aggressive cases metastasize to regional lymph nodes or distant organs. Identifying tumors at risk of metastasis remains challenging, particularly for the 16-30% of cases that lack clear clinical or histopathological high-risk features. In this study, we applied a mass spectrometry-based proteomic approach to profile archival primary cutaneous squamous cell carcinoma samples with and without confirmed metastasis. A total of 4819 protein groups were identified, of which 284 were differentially abundant between the groups. The differential abundance of a subset of proteins was further validated in silico using independent transcriptomic datasets. These proteins were enriched in pathways associated with metastatic hallmarks, including reduced apoptosis, decreased cell adhesion and differentiation, and increased angiogenesis and keratinocyte migration. Classification analysis using support vector machine models achieved an accuracy of 88.66% in predicting metastatic potential. Collectively, these findings demonstrate the potential of proteomics to improve metastatic risk stratification and guide the clinical management of cutaneous squamous cell carcinoma, ultimately supporting better patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia; Department of Dermatology, Westmead Hospital, Westmead, Australia; Centre for Cancer Research, The Westmead Instit…
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia; School of Mathematics and Statistics, Faculty of Science, The University of Sydney, Camperdown, Aus…
- The Skin Hospital, Darlinghurst, Australia.
- Department of Dermatology, Westmead Hospital, Westmead, Australia.
- Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Westmead, Australia; Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, Austr…
Förderung
- Western Sydney Local Health District
Zitieren
APA
Azimi, A., Patrick, E., Teh, R., Sholji, T., Araujo, R. R., Kim, J., & Fernandez-Penas, P. (2026). Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.08.025
Vancouver
Azimi A, Patrick E, Teh R, Sholji T, Araujo RR, Kim J, et al. Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas. Journal of Investigative Dermatology. 2026. doi:10.1016/j.jid.2026.08.025
BibTeX
@article{Azimi2026,
author = {Azimi, Ali and Patrick, Ellis and Teh, Rachel and Sholji, Tara and Araujo, Raquel Ruiz and Kim, Jennifer and Fernandez-Penas, Pablo},
title = {Proteomic signature predicts the metastatic risk of primary cutaneous squamous cell carcinomas},
journal = {Journal of Investigative Dermatology},
year = {2026},
doi = {10.1016/j.jid.2026.08.025}
}
EUVIMED